Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa

Chest

Volumn 142, Issue 5, 2012, Pages 1259-1266

  Ratjen, Felix ^a   Saiman, Lisa ^b   Mayer Hamblett, Nicole ^c   Lands, Larry C ^d   Kloster, Margaret ^c   Thompson, Valeria ^c   Emmett, Peggy ^e   Marshall, Bruce ^f   Accurso, Frank ^e   Sagel, Scott ^e   Anstead, Michael ^g  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f CYSTIC FIBROSIS FOUNDATION   (United States)

^g UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; C REACTIVE PROTEIN; CALGRANULIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MYELOPEROXIDASE; PLACEBO; SERUM AMYLOID A;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; DOUBLE BLIND PROCEDURE; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUTROPHIL COUNT; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT RESPONSE; WEIGHT CHANGE;

EID: 84866076450     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-0628     Document Type: Article

References (42)

1. Ratjen F, Döring G. Cystic fibrosis. Lancet. 2003;361(9358):681-689. (Pubitemid 36246556)
2. Flume PA, Mogayzel PJ Jr, Robinson KA, Rosenblatt RL, Quittell L, Marshall BC; Clinical Practice Guidelines for Pulmonary Therapies Committee; Cystic Fibrosis Foundation Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med. 2010;182(3):298-306.
3. Southern KW, Barker PM, Solis-Moya A, Patel L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2011;12(12):CD002203.
4. Labro MT. Cellular and molecular effects of macrolides on leukocyte function. Curr Pharm Des. 2004;10(25):3067-3080.
5. Tamaoki J, Kadota J, Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med. 2004;117(Suppl 9A):5S-11S.
6. Parnham MJ, Culi O, Erakovi V, et al. Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment. Eur J Pharmacol. 2005;517(1-2):132-143. (Pubitemid 40916224)
7. Miller MF, Martin JR, Johnson P, Ulrich JT, Rdzok EJ, Billing P. Erythromycin uptake and accumulation by human polymorphonuclear leukocytes and efficacy of erythromycin in killing ingested Legionella pneumophila. J Infect Dis. 1984;149(5):714-718. (Pubitemid 14108373)
8. Shinkai M, Foster GH, Rubin BK. Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2006;290(1):L75-L85.
9. Cigana C, Nicolis E, Pasetto M, Assael BM, Melotti P. Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun. 2006;350(4):977-982. (Pubitemid 44584188)
10. Cigana C, Assael BM, Melotti P. Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother. 2007;51(3):975-981. (Pubitemid 46355283)
11. Meyer M, Huaux F, Gavilanes X, et al. Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis. Am J Respir Cell Mol Biol. 2009;41(5):590-602.
12. Bergamini G, Cigana C, Sorio C, et al. Effects of azithromycin on glutathione S-transferases in cystic fibrosis airway cells. Am J Respir Cell Mol Biol. 2009;41(2):199-206.
13. Hillis GS, Pearson CV, Harding SA, et al. Effects of a brief course of azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome: A double-blind, randomized, placebo-controlled study. Am Heart J. 2004;148(1):72-79. (Pubitemid 38900481)
14. Davis SD, Brody AS, Emond MJ, Brumback LC, Rosenfeld M. Endpoints for clinical trials in young children with cystic fibrosis. Proc Am Thorac Soc. 2007;4(4):418-430. (Pubitemid 47333916)
15. Sagel SD, Chmiel JF, Konstan MW. Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc Am Thorac Soc. 2007;4(4):406-417. (Pubitemid 47330878)
16. Saavedra MT, Hughes GJ, Sanders LA, et al. Circulating RNA transcripts identify therapeutic response in cystic fibrosis lung disease. Am J Respir Crit Care Med. 2008;178(9):929-938.
17. Laguna TA, Wagner BD, Luckey HK, et al. Sputum desmosine during hospital admission for pulmonary exacerbation in cystic fibrosis. Chest. 2009;136(6):1561-1568.
18. Saiman L, Anstead M, Mayer-Hamblett N, et al; AZ0004 Azithromycin Study Group. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2010;303(17):1707-1715.
19. Wang X, Dockery DW, Wypij D, et al. Pulmonary function growth velocity in children 6 to 18 years of age. Am Rev Respir Dis. 1993;148(6 pt 1):1502-1508. (Pubitemid 24002478)
20. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax. 2002;57(3):212-216. (Pubitemid 34214405)
21. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet. 2002;360(9338):978-984. (Pubitemid 35284109)
22. Saiman L, Marshall BC, Mayer-Hamblett N, et al Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290(13):1749-1756. (Pubitemid 37430625)
23. Hansen CR, Pressler T, Koch C, Høiby N. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J Cyst Fibros. 2005;4(1):35-40. (Pubitemid 40347775)
24. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP. Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial. Thorax. 2006;61(10):895-902. (Pubitemid 44570311)
25. Steinkamp G, Schmitt-Grohe S, Döring G, et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respir Med. 2008;102(11):1643-1653.
26. Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E, Zarogoulidis K. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol. 2012;65(5):479-503.
27. Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med. 2003;168(1):121-125. (Pubitemid 37046642)
28. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2006;174(5):566-570. (Pubitemid 44330550)
29. Friesen CA, Wiens LA, Burry VF, Portnoy J, Roberts CC. C-reactive protein in acute pulmonary exacerbations of patients with cystic fibrosis. Pediatr Pulmonol. 1995;20(4):215-219. (Pubitemid 3007379)
30. Levy H, Kalish LA, Huntington I, et al. Inflammatory markers of lung disease in adult patients with cystic fibrosis. Pediatr Pulmonol. 2007;42(3):256-262. (Pubitemid 46417699)
31. Smith JW, Colombo JL, McDonald TL. Comparison of serum amyloid A and C-reactive protein as indicators of lung inflammation in corticosteroid treated and non-corticosteroid treated cystic fibrosis patients. J Clin Lab Anal. 1992;6(4):219-224.
32. McGrath LT, Mallon P, Dowey L, et al. Oxidative stress during acute respiratory exacerbations in cystic fibrosis. Thorax. 1999;54(6):518-523. (Pubitemid 29241624)
33. Marhaug G, Permin H, Husby G. Amyloid-related serum protein (SAA) as an indicator of lung infection in cystic fibrosis. Acta Paediatr Scand. 1983;72(6):861-866. (Pubitemid 14239755)
34. Gray RD, Imrie M, Boyd AC, Porteous D, Innes JA, Greening AP. Sputum and serum calprotectin are useful biomarkers during CF exacerbation. J Cyst Fibros. 2010;9(3):193-198.
35. Konstan MW, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med. 1994;150(2):448-454. (Pubitemid 24252357)
36. Paul K, Rietschel E, Ballmann M, et al Bronchoalveolar Lavage for the Evaluation of Antiinflammatory Treatment Study Group. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med. 2004;169(6):719-725. (Pubitemid 38338924)
37. Stríz I, Trebichavský I. Calprotectin-a pleiotropic molecule in acute and chronic inflammation. Physiol Res. 2004;53(3):245-253. (Pubitemid 38797280)
38. Corbin BD, Seeley EH, Raab A, et al. Metal chelation and inhibition of bacterial growth in tissue abscesses. Science. 2008;319(5865):962-965. (Pubitemid 351263768)
39. Urban CF, Ermert D, Schmid M, et al. Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog. 2009;5(10):e1000639.
40. Loser K, Vogl T, Voskort M, et al. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat Med. 2010;16(6):713-717.
41. Thewissen M, Damoiseaux J, van de Gaar J, Tervaert JW. Neutrophils and T cells: bidirectional effects and functional interferences. Mol Immunol. 2011;48(15-16):2094-2101.
42. Tan HL, Regamey N, Brown S, Bush A, Lloyd CM, Davies JC. The Th17 pathway in cystic fibrosis lung disease. Am J Respir Crit Care Med. 2011;184(2):252-258.